PDS Biotechnology (NASDAQ:PDSB) Stock Price Up 9.1% – Time to Buy?

PDS Biotechnology Corporation (NASDAQ:PDSB)’s share price rose 9.1% during mid-day trading on Tuesday . The stock traded as high as $0.7349 and last traded at $0.69. Approximately 1,179,573 shares traded hands during trading, an increase of 279% from the average daily volume of 311,310 shares. The stock had previously closed at $0.6327.

Wall Street Analysts Forecast Growth

PDSB has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Thursday, January 22nd. B. Riley Financial decreased their target price on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, November 25th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Stock Up 9.1%

The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The stock has a 50-day moving average of $0.78 and a 200-day moving average of $0.89. The firm has a market cap of $36.14 million, a price-to-earnings ratio of -0.84 and a beta of 1.20.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors have recently modified their holdings of PDSB. Armistice Capital LLC bought a new stake in PDS Biotechnology in the 4th quarter valued at about $2,182,000. Commonwealth Equity Services LLC boosted its stake in PDS Biotechnology by 117.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares during the period. Geode Capital Management LLC grew its position in PDS Biotechnology by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after purchasing an additional 38,399 shares during the last quarter. Susquehanna International Group LLP grew its position in PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares during the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares during the period. Institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.